Ukr.Biochem.J. 2022; Volume 94, Issue 6, Nov-Dec, pp. 3-10

doi: https://doi.org/10.15407/ubj94.06.003

Computational investigation of honeybee venom proteins as potential Omicron SARS-CoV-2 inhibitors

13.02.2023   Uncategorized   No comments

H. A. Al-Madhagi1*, M. G. Saleh2

1Biochemical Technology Program, Faculty of Applied Sciences, Dhamar University, Yemen;
2Division of Microbiology, Biology Department, Faculty of Applied Sciences, Dhamar University, Yemen;
*e-mail: bio.haitham@gmail.com

Received: 01 October 2022; Revised: 07 November 2022;
Accepted: 17 February 2023; Available on-line:  27 February 2023

Because of the catastrophic consequences of COVID-19 on the world population, there should be novel­ interventions to handle ongoing infections and daily death cases. The aim of the current study is to examine the effectiveness of HBV (Honeybee venom) proteins on spike protein RBD by in silico tools. The sequences of 5 HBV proteins were used for homology modeling by Phyre 2. The generated protein models were employed for protein-protein docking against Omicron Spike glycoprotein receptor binding domain (RBD) (PDB ID# 7T9L) through HDock and ClusPro platforms followed by prediction of binding affinity using PRODIGY web portal and PDBsum for revealing interaction details. It was found that all of the examined HBV proteins exhibi­ted strong docking scores and binding affinity profiles toward RBD. The findings of the present study indicate the possible HBV as preventive as well as treatment options against Omicron SARS-CoV-2.

Keywords: , , , ,

References:

  1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534. PubMed, PubMedCentral, CrossRef
  2. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. PubMed, PubMedCentral, CrossRef
  3. Leung C. Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China. Mech Ageing Dev. 2020;188:111255. PubMed, PubMedCentral, CrossRef
  4. Shapira T, Monreal IA, Dion SP, Buchholz DW, Imbiakha B, Olmstead A, Jager M, Désilets A, Gao G, Martins M, Vandal T, Thompson CAH, Chin A, Rees WD, Steiner T, Nabi IR, Marsault E, Sahler J, Diel DG, Van de Walle GR, August A, Whittaker GR, Boudreault PL, Leduc R, Aguilar HC, Jean F. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022;605(7909):340-348. PubMed, PubMedCentral, CrossRef
  5. Del Rio C, Omer SB, Malani PN. Winter of Omicron-The Evolving COVID-19 Pandemic. JAMA. 2022;327(4):319-320. PubMed, CrossRef
  6. Del Rio C, Malani PN. COVID-19 in 2022-The Beginning of the End or the End of the Beginning? JAMA. 2022;327(24):2389-2390. PubMed, PubMedCentral, CrossRef
  7. Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, Leigh JP, Hu J, El-Mohandes A. Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun. 2022;13(1):3801. PubMed, PubMedCentral, CrossRef
  8. Kim YS, Chung HS, Noh SG, Lee B, Chung HY, Choi JG. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor. Int J Mol Sci. 2021;22(16):8604. PubMed, PubMedCentral, CrossRef
  9. Lu Q, Zhang Z, Li H, Zhong K, Zhao Q, Wang Z, Wu Z, Yang D, Sun S, Yang N, Zheng M, Chen Q, Long C, Guo W, Yang H, Nie C, Tong A. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J Nanobiotechnology. 2021;19(1):33. PubMed, PubMedCentral, CrossRef
  10. Pramanik A, Sharma PC, Patibandla S, Gao Y, Ruppa-Kasani V, Goli J, Kumar A, Chatterjee A, Sinha SS, Bates JT, Bierdeman MA, Tandon R, Ray PC. Blocking SARS-CoV-2 Delta Variant (B.1.617.2) Spike Protein Receptor-Binding Domain Binding with the ACE2 Receptor of the Host Cell and Inhibiting Virus Infections Using Human Host Defense Peptide-Conjugated Graphene Quantum Dots. ACS Omega. 2022;7(9):8150-8157. PubMed, PubMedCentral, CrossRef
  11. Wei C, Shan KJ, Wang W, Zhang S, Huan Q, Qian W. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. J Genet Genomics. 2021;48(12):1111-1121. PubMed, PubMedCentral, CrossRef
  12. da Costa CHS, de Freitas CAB, Alves CN, Lameira J. Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. Sci Rep. 2022;12(1):8540. PubMed, PubMedCentral, CrossRef
  13. Lim H, Baek A, Kim J, Kim MS, Liu J, Nam KY, Yoon J, No KT. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method. Sci Rep. 2020;10(1):16862. PubMed, PubMedCentral, CrossRef
  14. Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, Cui X, Xiao J, Meng T, Zhou W, Liu J, Xu H. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020. CrossRef
  15. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro L, Ho DD. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29(5):747-751.e4. PubMed, PubMedCentral, CrossRef
  16. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220. PubMed, CrossRef
  17. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-1149. PubMed, PubMedCentral, CrossRef
  18. Li L, Han P, Huang B, Xie Y, Li W, Zhang D, Han P, Xu Z, Bai B, Zhou J, Kang X, Li X, Zheng A, Zhang R, Qiao S, Zhao X, Qi J, Wang Q, Liu K, Gao GF. Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s. Cell Discov. 2022;8(1):65. PubMed, PubMedCentral, CrossRef
  19. Abdela N, Jilo K. Bee venom and its therapeutic values: a review. Adv Life Sci Technol. 2016;44:18–22.
  20. Hwang DS Kim SK, Bae H. Therapeutic Effects of Bee Venom on Immunological and Neurological Diseases. Toxins (Basel). 2015;7(7):2413-2421. PubMed, PubMedCentral, CrossRef
  21. Kasozi KI, Niedbała G, Alqarni M, Zirintunda G, Ssempijja F, Musinguzi SP, Usman IM, Matama K, Hetta HF, Mbiydzenyuy NE, El-Saber Batiha G, Beshbishy AM, Welburn SC. Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections. Front Public Health. 2020;8:594458. PubMed, PubMedCentral, CrossRef
  22. Muzammal M, Khan MA, Mohaini MA, Alsalman AJ, Hawaj MAA, Farid A. In Silico Analysis of Honeybee Venom Protein Interaction with Wild Type and Mutant (A82V + P375S) Ebola Virus Spike Protein. Biologics. 2022;2(1):45–55. CrossRef
  23. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47(D1):D506-D515. PubMed, PubMedCentral, CrossRef
  24. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc. 2015;10(6):845-858. PubMed, PubMedCentral, CrossRef
  25. Lee GR, Won J, Heo L, Seok C. GalaxyRefine2: simultaneous refinement of inaccurate local regions and overall protein structure. Nucleic Acids Res. 2019;47(W1):W451-W455. PubMed, PubMedCentral, CrossRef
  26. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(2):283–291. CrossRef
  27. Pawar SS, Rohane SH. Review on discovery studio: An important tool for molecular docking. Asian J Res Chem. 2021;14(1):86–88. CrossRef
  28. Yan Y, Zhang D, Zhou P, Li B, Huang SY. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017;45(W1):W365-W373. PubMed, PubMedCentral, CrossRef
  29. Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, Beglov D, Vajda S. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12(2):255-278. PubMed, PubMedCentral, CrossRef
  30. Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics. 2016;32(23):3676-3678. PubMed, CrossRef
  31. DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 Newsl Protein Crystallogr. 2002;40:82–92.
  32. Maslow JN. The cost and challenge of vaccine development for emerging and emergent infectious diseases. Lancet Glob Health. 2018;6(12):e1266-e1267. PubMed, PubMedCentral, CrossRef
  33. Bansal P, Kumar R, Singh J, Dhanda S. In silico molecular docking of SARS-CoV-2 surface proteins with microbial non-ribosomal peptides: identification of potential drugs. J Proteins Proteom. 2021;12(3):177-184. PubMed, PubMedCentral, CrossRef
  34. Fakih T. Dermaseptin-Based Antiviral Peptides to Prevent COVID-19 through In Silico Molecular Docking Studies against SARS-CoV-2 Spike Protein. Pharm Sci Res. 2020;7(4):65-70. CrossRef
  35. MubarakAli D, MohamedSaalis J, Sathya R, Irfan N, Kim JW. An evidence of microalgal peptides to target spike protein of COVID-19: In silico approach. Microb Pathog. 2021;160:105189. PubMed, PubMedCentral, CrossRef
  36. Shishir TA, Jannat T, Naser IB. An in-silico study of the mutation-associated effects on the spike protein of SARS-CoV-2, Omicron variant. PLoS One. 2022;17(4):e0266844. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.